The Global Advanced Therapy Medicinal Products CDMO Market will Hit $11.9 Billion by 2028, at a CAGR of 16.3%

Advanced Therapy Medicinal Products CDMO Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Advanced Therapy Medicinal Products CDMO Market size is expected to reach $11.9 billion by 2028, rising at a market growth of 16.3% CAGR during the forecast period.

The Cardiology segment is showcasing a CAGR of 16.8% during (2022 - 2028). Growth of the segment is ascribed to the rising incidence of cardiovascular diseases (CVDs) and the cooperation in research for the creation of cutting-edge treatments. In the entire world, CVDs are the main cause of death. According to World Health Organization (WHO), 17.9 million deaths worldwide in 2019 were attributable to CVDs. Stroke and heart attack deaths accounted for 85% of these fatalities.

The Gene Therapy segment acquired maximum revenue share in the Global Advanced Therapy Medicinal Products CDMO Market by Product in 2021 thereby, achieving a market value of $5.8 billion by 2028. For drug firms, politicians, and academics, the trend of developments in gene therapy techniques, vectors, and targets may be instructive. Recent developments in gene treatments have made it possible to treat a variety of illnesses, from solid malignancies to congenital abnormalities.

The Phase II segment has shown the growth rate of 16.4% during (2022 - 2028). Due to the significant clearance rate of phase 1 of clinical studies, phase 2 clinical studies contain the majority of emerging ATMPs. The segment is being driven by a rise in the number of goods in phase 2. Phase 2 trials are often randomized, controlled studies that assess a drug's safety and efficacy for a specific ailment. Participants are chosen based on strict criteria to enable close monitoring of a patient population that is generally homogeneous.

The North America market dominated the Global Advanced Therapy Medicinal Products CDMO Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5.7 billion by 2028. The Europe market is exhibiting a CAGR of 16.5% during (2022 - 2028). Additionally, The Asia Pacific market would display a CAGR of 16.9% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/advanced-therapy-medicinal-products-cdmo-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)

Global Advanced Therapy Medicinal Products CDMO Market Segmentation

By Indication

• Oncology
• Cardiology
• Central Nervous System & Musculoskeletal
• Infectious Disease
• Dermatology
• Endocrine, Metabolic, Genetic
• Immunology & Inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

By Product

• Gene Therapy
• Cell Therapy
• Tissue Engineered & Others

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Thermo Fisher Scientific, Inc. (Patheon, Inc.)
• AGC Biologics, Inc. (AGC, Inc.)
• Catalent, Inc.
• Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
• WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
• Lonza Group AG
• Celonic AG (JRS PHARMA GmbH & Co. KG)
• Rentschler Biopharma SE
• Bio Elpida (Polyplus-transfection SA.)

Unique Offerings from KBV Research

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Related Reports:

North America Advanced Therapy Medicinal Products CDMO Market size & Opportunities 2022-2028

Europe Advanced Therapy Medicinal Products CDMO Market & Growth Forecast 2022-2028

Asia Pacific Advanced Therapy Medicinal Products CDMO Market Share & Industry Outlook to 2028

LAMEA Advanced Therapy Medicinal Products CDMO Market Growth, Trends & Forecasts 2022-2028